Abstract
After local microwave coagulation and subsequent intra-tumoural injection of microparticles encapsulating interleukin-2 and granulocyte-macrophage colony-stimulating factor, the anti-tumour efficacy against subcutaneous Lewis lung carcinoma in syngeneic mice was evaluated. This treatment elicited a potent systemic anti-tumour immunity that protected treated mice from re-challenge with the same tumour cells and caused the distal tumours in a bilateral tumour model to be rejected. Cytotoxicity assay indicated that both T- and natural killer cells acted as the effector cells in the anti-tumour immunity. These data highlight the feasibility of microwave-pre-treated in situ cancer vaccination for clinical use.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
CD3 Complex / immunology
-
Cancer Vaccines*
-
Carcinoma, Lewis Lung / pathology
-
Carcinoma, Lewis Lung / radiotherapy*
-
Carcinoma, Lewis Lung / surgery
-
Cell Line, Tumor
-
Electrocoagulation / methods*
-
Female
-
Graft Rejection
-
Granulocyte-Macrophage Colony-Stimulating Factor / genetics
-
Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
-
Humans
-
Interleukin-2 / genetics
-
Interleukin-2 / pharmacology
-
Killer Cells, Natural / immunology
-
Lung Neoplasms / pathology
-
Lung Neoplasms / radiotherapy*
-
Lung Neoplasms / surgery
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Microspheres
-
Microwaves / therapeutic use*
-
Neoplasm Transplantation
-
Recombinant Proteins / pharmacology
-
T-Lymphocytes, Cytotoxic / immunology
-
Tumor Burden
Substances
-
CD3 Complex
-
Cancer Vaccines
-
Interleukin-2
-
Recombinant Proteins
-
Granulocyte-Macrophage Colony-Stimulating Factor